(Reuters) – Britain’s Oxford Biomedica said on Friday it had signed a new three-year agreement to manufacture AstraZeneca’s COVID-19 vaccine beyond 2022.
Oxford Biomedica, whose commitments under a previous deal for AstraZeneca’s vaccine will end at the end of 2022, said it expected to record about 30 million pounds ($36.4 million) in revenue from the contract in the current financial year.
($1 = 0.8241 pounds)
(Reporting by Amna Karimi in Bengaluru; Editing by Anil D’Silva)
